These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31934816)

  • 1. Morphological Reconstitution and Persistent Changes After Intravitreal Ocriplasmin for Vitreomacular Traction and Macular Hole.
    Zandi S; Freiberg F; Vaclavik V; Pfister IB; Traine PG; Kaya C; Michels S; Garweg JG
    J Ocul Pharmacol Ther; 2020 Mar; 36(2):126-132. PubMed ID: 31934816
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
    Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
    Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
    Hager A; Seibel I; Riechardt A; Rehak M; Joussen AM
    Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes.
    Sharma P; Juhn A; Houston SK; Fineman M; Chiang A; Ho A; Regillo C
    Am J Ophthalmol; 2015 May; 159(5):861-7.e2. PubMed ID: 25660387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
    Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome.
    Vasquez DH; Altamirano JC; Casaus A; Del Valle RA; Gonzalez R; Gonzalez-De La Rosa A; Navarro-Partida J; Vasquez MA; Santos A
    Curr Eye Res; 2018 Feb; 43(2):208-212. PubMed ID: 29111823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
    Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
    Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
    Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
    Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical Outcomes for Persistent Macular Hole After Ocriplasmin.
    Lee GD; Taney LS; Rogers AH; Shah CP; Duker JS; Baumal CR
    Ophthalmic Surg Lasers Imaging Retina; 2015; 46(7):732-6. PubMed ID: 26247454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASSESSMENT OF ANATOMICAL AND FUNCTIONAL OUTCOMES WITH OCRIPLASMIN TREATMENT IN PATIENTS WITH VITREOMACULAR TRACTION WITH OR WITHOUT MACULAR HOLES: Results of OVIID-1 Trial.
    Tadayoni R; Holz FG; Zech C; Liu X; Spera C; Stalmans P
    Retina; 2019 Dec; 39(12):2341-2352. PubMed ID: 30308558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Initial Clinical Experiences Using Ocriplasmin for the Treatment of Vitreomacular Traction with or without a Macular Hole].
    Lenk J; Matthé E; Ventzke S; Pillunat LE; Sandner D
    Klin Monbl Augenheilkd; 2018 Jan; 235(1):73-80. PubMed ID: 28282697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal ocriplasmin for the treatment of vitreomacular traction and macular hole- A study of efficacy and safety based on NICE guidance.
    Muqit MMK; Hamilton R; Ho J; Tucker S; Buck H
    PLoS One; 2018; 13(5):e0197072. PubMed ID: 29768451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.
    Schumann RG; Langer J; Compera D; Luedtke K; Schaumberger MM; Kreutzer T; Mayer WJ; Wolf A; Priglinger SG
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2081-2089. PubMed ID: 28755165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications of intravitreal ocriplasmin for vitreomacular traction and macular hole: a prospective spectral-domain optical coherence tomography study.
    Chatziralli IP; Theodossiadis GP; Parikakis E; Datseris I; Theodossiadis P
    Cutan Ocul Toxicol; 2016 Dec; 35(4):263-9. PubMed ID: 26555379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
    Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
    Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.
    Abou Ltaif S; Herbert L
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional improvement assessed by multifocal electroretinogram after Ocriplasmin treatment for vitreomacular traction.
    Rossi S; Testa F; Melillo P; Orrico A; Della Corte M; Simonelli F
    BMC Ophthalmol; 2016 Jul; 16():110. PubMed ID: 27430356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study.
    Greven MA; Garg S; Chiu B; Shah SP; Wolfe J; Fine HF; Roth DB; Robinson J; Mong J; Hsu J; Regillo C; Ho A; Haller JA
    Br J Ophthalmol; 2016 Sep; 100(9):1211-5. PubMed ID: 26659344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
    Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
    Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics.
    Bertelmann T; Berndzen L; Raber T; Pfeiffer S; Leha A; Paul C; Feltgen N; Bemme S
    Sci Rep; 2021 Dec; 11(1):24096. PubMed ID: 34916576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.